vs
MARCUS CORP（MCS）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是MARCUS CORP的1.1倍（$207.3M vs $193.5M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 2.8%），MARCUS CORP自由现金流更多（$26.4M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 18.2%）
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
MCS vs RARE — 直观对比
营收规模更大
RARE
是对方的1.1倍
$193.5M
营收增速更快
RARE
高出23.1%
2.8%
自由现金流更多
MCS
多$127.2M
$-100.8M
两年增速更快
RARE
近两年复合增速
18.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $193.5M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 0.9% | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | 2.8% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MCSRARE
| Q4 25 | $193.5M | $207.3M | ||
| Q3 25 | $210.2M | $159.9M | ||
| Q2 25 | $206.0M | $166.5M | ||
| Q1 25 | $148.8M | $139.3M | ||
| Q4 24 | $188.3M | $164.6M | ||
| Q3 24 | $232.7M | $139.5M | ||
| Q2 24 | $176.0M | $147.0M | ||
| Q1 24 | $138.5M | $108.8M |
净利润MCSRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $16.2M | $-180.4M | ||
| Q2 25 | $7.3M | $-115.0M | ||
| Q1 25 | $-16.8M | $-151.1M | ||
| Q4 24 | $986.0K | $-133.2M | ||
| Q3 24 | $23.3M | $-133.5M | ||
| Q2 24 | $-20.2M | $-131.6M | ||
| Q1 24 | $-11.9M | $-170.7M |
营业利润率MCSRARE
| Q4 25 | 0.9% | -54.7% | ||
| Q3 25 | 10.8% | -106.9% | ||
| Q2 25 | 6.3% | -64.8% | ||
| Q1 25 | -13.7% | -102.6% | ||
| Q4 24 | -1.2% | -74.3% | ||
| Q3 24 | 14.1% | -94.6% | ||
| Q2 24 | 1.3% | -79.1% | ||
| Q1 24 | -12.0% | -151.9% |
净利率MCSRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | 7.7% | -112.8% | ||
| Q2 25 | 3.6% | -69.0% | ||
| Q1 25 | -11.3% | -108.5% | ||
| Q4 24 | 0.5% | -80.9% | ||
| Q3 24 | 10.0% | -95.7% | ||
| Q2 24 | -11.5% | -89.5% | ||
| Q1 24 | -8.6% | -156.8% |
每股收益（稀释后）MCSRARE
| Q4 25 | — | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.4M | $421.0M |
| 总债务越低越好 | $159.0M | — |
| 股东权益账面价值 | $457.4M | $-80.0M |
| 总资产 | $1.0B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.35× | — |
8季度趋势，按日历期对齐
现金及短期投资MCSRARE
| Q4 25 | $23.4M | $421.0M | ||
| Q3 25 | $7.4M | $202.5M | ||
| Q2 25 | $14.9M | $176.3M | ||
| Q1 25 | $11.9M | $127.1M | ||
| Q4 24 | $40.8M | $174.0M | ||
| Q3 24 | $28.4M | $150.6M | ||
| Q2 24 | $32.8M | $480.7M | ||
| Q1 24 | $17.3M | $112.3M |
总债务MCSRARE
| Q4 25 | $159.0M | — | ||
| Q3 25 | $162.0M | — | ||
| Q2 25 | $179.9M | — | ||
| Q1 25 | $198.9M | — | ||
| Q4 24 | $159.1M | — | ||
| Q3 24 | $173.1M | — | ||
| Q2 24 | $175.7M | — | ||
| Q1 24 | $169.8M | — |
股东权益MCSRARE
| Q4 25 | $457.4M | $-80.0M | ||
| Q3 25 | $454.3M | $9.2M | ||
| Q2 25 | $448.4M | $151.3M | ||
| Q1 25 | $441.8M | $144.2M | ||
| Q4 24 | $464.9M | $255.0M | ||
| Q3 24 | $462.3M | $346.8M | ||
| Q2 24 | $449.4M | $432.4M | ||
| Q1 24 | $459.3M | $140.3M |
总资产MCSRARE
| Q4 25 | $1.0B | $1.5B | ||
| Q3 25 | $1.0B | $1.2B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $1.0B | $1.3B | ||
| Q4 24 | $1.0B | $1.5B | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B | ||
| Q1 24 | $1.0B | $1.3B |
负债/权益比MCSRARE
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.34× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.39× | — | ||
| Q1 24 | 0.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.8M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $26.4M | $-100.8M |
| 自由现金流率自由现金流/营收 | 13.6% | -48.6% |
| 资本支出强度资本支出/营收 | 11.6% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $989.0K | $-472.0M |
8季度趋势，按日历期对齐
经营现金流MCSRARE
| Q4 25 | $48.8M | $-99.8M | ||
| Q3 25 | $39.1M | $-91.4M | ||
| Q2 25 | $31.6M | $-108.3M | ||
| Q1 25 | $-35.3M | $-166.5M | ||
| Q4 24 | $52.6M | $-79.3M | ||
| Q3 24 | $30.5M | $-67.0M | ||
| Q2 24 | $36.0M | $-77.0M | ||
| Q1 24 | $-15.1M | $-190.7M |
自由现金流MCSRARE
| Q4 25 | $26.4M | $-100.8M | ||
| Q3 25 | $18.2M | $-92.7M | ||
| Q2 25 | $14.7M | $-110.7M | ||
| Q1 25 | $-58.3M | $-167.8M | ||
| Q4 24 | $27.1M | $-79.5M | ||
| Q3 24 | $12.0M | $-68.6M | ||
| Q2 24 | $16.1M | $-79.0M | ||
| Q1 24 | $-30.5M | $-193.9M |
自由现金流率MCSRARE
| Q4 25 | 13.6% | -48.6% | ||
| Q3 25 | 8.7% | -58.0% | ||
| Q2 25 | 7.1% | -66.5% | ||
| Q1 25 | -39.2% | -120.5% | ||
| Q4 24 | 14.4% | -48.3% | ||
| Q3 24 | 5.2% | -49.2% | ||
| Q2 24 | 9.2% | -53.7% | ||
| Q1 24 | -22.0% | -178.2% |
资本支出强度MCSRARE
| Q4 25 | 11.6% | 0.5% | ||
| Q3 25 | 9.9% | 0.8% | ||
| Q2 25 | 8.2% | 1.5% | ||
| Q1 25 | 15.5% | 1.0% | ||
| Q4 24 | 13.5% | 0.1% | ||
| Q3 24 | 7.9% | 1.2% | ||
| Q2 24 | 11.3% | 1.4% | ||
| Q1 24 | 11.1% | 3.0% |
现金转化率MCSRARE
| Q4 25 | — | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | 4.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 53.31× | — | ||
| Q3 24 | 1.31× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
